湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2025-040 湖南方盛制药股份有限公司 关于提请股东大会授权董事会制定并执行公司 2025 年中期现金分红方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次提请股东大会授权董事会制定公司2025年中期分红的方案需提交2024年年 度股东大会审议。 湖南方盛制药股份有限公司（以下简称"公司"）根据《中 华人民共和国公司法》《上市公司章程指引》《上市公司监管指 引第 3 号——上市公司现金分红》《上海证券交易所上市公司自 律监管指引第 1 号——规范运作》等相关法律、法规、规范性文 件及《公司章程》规定，为进一步提高分红频次，增强投资者回 报水平，结合公司实际情况，公司董事会提请股东大会授权董事 会，在授权范围内制定并实施公司 2025 年中期分红方案，具体 安排如下： 一、2025 年中期现金分红安排 1、中期分红包括季度分红、半年度分红 ...

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2025-039 湖南方盛制药股份有限公司 关于 2024 年年度利润分配方案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例：每股派发现金红利 0.20 元（含税）； 本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日期将在权 益分派实施公告中明确； 在实施权益分派的股权登记日前公司总股本发生变动的，拟维持分配比例不变， 相应调整分配总额，并将在相关公告中披露； 不触及《上海证券交易所股票上市规则（2024 年 4 月修订）》（以下简称《股 票上市规则》）第 9.8.1 条第一款第（八）项规定的可能被实施其他风险警示的情形。 一、利润分配方案内容 （一）利润分配方案的具体内容 经上会会计师事务所（特殊普通合伙）审计，截至 2024 年 12 月 31 日，公司母公司报表中期末未分配利润为人民币 856,270,971.83 ...

关于湖南方盛制药股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审核报告 上会师报字(2025)第 3433 号 上会会计师事务所（特殊普通合伙） 中国 上海 我们接受委托,依据《中国注册会计师执业准则》审计了湖南方盛制药股份有 限公司(以下简称"贵公司")2024年度的财务报表,包括 2024年 12月 31 日的合并 及母公司资产负债表,2024年度的合并及母公司利润表、合并及母公司现金流量表、 合并及母公司所有者权益变动表及财务报表附注,并于 2025年 4月 25 日出具了审计 报告(报告书编号为:上会师报字(2025)第 3431 号)。在此基础上,我们审核了后附 的贵公司管理层编制的"湖南方盛制药股份有限公司 2024年度非经营性资金占用及 其他关联资金往来情况汇总表"(以下简称"汇总表")。 贵公司管理层的责任是提供真实、合法、完整的相关资料,按照《上市公司监 管指引第 8 号 -- 上市公司资金往来、对外担保的监管要求》的规定,编制和披露 后附的汇总表,并保证其内容真实、准确、完整,不存在虚假记载、误导性陈述或 重大遗漏。 · 计师 李 务所(特殊普通个 Centified ...

关于湖南方盛制药股份有限公司 会计估计变更事项专项说明的 专项审核报告 上会师报字(2025)第 7897 号 我们接受委托，审核了后附的湖南方盛制药股份有限公司（以 下简称"贵公司"）《关于湖南方盛制药股份有限公司会计估计变更 事项专项说明》（以下简称"专项说明"）。 一、管理层责任 按照《企业会计准则第 28 号——会计政策、会计估计变更和差 错更正》以及《上海证券交易所上市公司自律监管指南第 2 号—— 业务办理》的相关规定编制专项说明，并保证其内容真实、准确、 完整，不存在虚假记载、误导性陈述或重大遗漏是贵公司管理层的 责任。 二、注册会计师的责任 我们的责任是在实施审核程序的基础上对专项说明提出审核结 论。我们的审核是参照《中国注册会计师其他鉴证业务准则第 3101 号——历史财务信息审计或审阅以外的鉴证业务》的相关规定进行 的，在审核过程中，我们结合贵公司本次会计估计变更的实际情况， 实施了询问、检查记录和文件、重新计算以及我们认为必要的其他 第 1 页 共 2 页 程序。我们相信，我们的工作为发表审核意见提供了合理的基础。 三、审核结论 我们认为，上述《关于湖南方盛制药股份有限公司会计估计变 更 ...

关于湖南方盛制药股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 我们的责任是在执行审核工作的基础上对汇总表发表专项审核意见。 我们按照中国注册会计师审计准则的相关规定执行了审核工作。中国注册 会计师审计准则要求我们遵循中国注册会计师职业道德守则，计划和执行审核 工作对汇总表是否不存在重大错报获取合理保证。在审核的过程中，我们实施 了包括检查会计记录、重新计算相关项目金额等我们认为必要的程序。我们相 信，我们的审核工作为发表审核意见提供了合理的基础。 我们认为，贵公司管理层编制的汇总表在所有重大方面符合《上市公司监 管指引第 8 号——上市公司资金往来、对外担保的监管要求》的规定，如实反 映了湖南方盛制药股份有限公司 2024 年度非经营性资金占用及其他关联资金往 来情况，后附汇总表所载资料与贵公司 2024 年度已审的会计报表及相关资料的 内容在所有重大方面未发现不一致。 为了更好的理解贵公司 2024 年度非经营性资金占用及其他关联资金往来情 况，汇总表应当与已审计的 2024 年度财务报表一并阅读。 目 录 1、 专项审计报告 2、 附表 委托单位：湖南方盛制药股份有限公司 审 ...

关于湖南方盛制药股份有限公司 会计估计变更事项专项说明的 专项审核报告 上会师报字(2025)第 7897 号 上会会计师事务所 (特殊普通合伙) 中国 上海 令计师 李今所（特殊普通合伙） ai Cortified Public Accountants (Spocial 关于湖南方盛制药股份有限公司 会计估计变更事项专项说明的 专项审核报告 上会师报字(2025)第 7897 号 湖南方盛制药股份有限公司董事会: 我们接受委托,审核了后附的湖南方盛制药股份有限公司(以下简称"贵公司") 《关于湖南方盛制药股份有限公司会计估计变更事项专项说明》(以下简称"专项说 明"）。 一、管理层责任 二、注册会计师的责任 我们的责任是在实施审核程序的基础上对专项说明提出审核结论。我们的审核 是参照《中国注册会计师其他鉴证业务准则第 3101 号——历史财务信息审计或审阅 以外的鉴证业务》的相关规定进行的，在审核过程中，我们结合贵公司本次会计估 计变更的实际情况,实施了询问、检查记录和文件、重新计算以及我们认为必要的 其他程序。我们相信,我们的工作为发表审核意见提供了合理的基础。 ·计师 李务所（特殊普通合伙） liod ...

Financial Performance - The company's operating revenue for 2024 reached ¥1,777,494,393.87, representing a year-on-year increase of 9.15% compared to ¥1,628,542,252.04 in 2023[23]. - Net profit attributable to shareholders for 2024 was ¥255,216,208.09, a significant increase of 36.61% from ¥186,823,361.94 in 2023[23]. - The net profit after deducting non-recurring gains and losses was ¥193,089,411.89, up 44.61% from ¥133,527,499.83 in the previous year[23]. - The company's total assets increased by 6.02% to ¥3,266,573,464.59 at the end of 2024, compared to ¥3,080,985,669.36 at the end of 2023[23]. - The basic earnings per share for 2024 was ¥0.59, a 37.21% increase from ¥0.43 in 2023[24]. - The weighted average return on net assets rose to 16.60%, an increase of 4.02 percentage points from 12.58% in 2023[24]. - The cash flow from operating activities for 2024 was ¥194,947,438.56, a substantial increase of 122.70% from ¥87,537,942.80 in 2023[23]. Dividend Distribution - The board approved a cash dividend of 2.00 RMB per 10 shares, totaling approximately 136.13 million RMB, which represents 53.34% of the net profit attributable to shareholders[6]. - The company distributed a total of 21.96 million RMB in cash dividends for the first half of 2024 and 26.35 million RMB for the special dividend[6]. - The company has executed a stable cash dividend policy, with a total dividend payout of approximately 623 million RMB since its listing, including a planned annual dividend of 136 million RMB for 2024[45]. Research and Development - The company plans to continue its focus on research and development of new products and technologies to enhance market competitiveness[7]. - Research and development expenses increased by nearly 30% year-on-year, reflecting the company's commitment to enhancing its new drug development capabilities[24]. - The company launched 8 new innovative traditional Chinese medicine projects, with Yiqi Xiaoliu Granules receiving clinical trial approval[38]. - The company is currently developing 49 projects in chemical generic drugs and active pharmaceutical ingredients, with 7 projects submitted for approval[39]. - The company’s R&D expenditure is significantly lower than some peers, such as Tianjin Pharmaceutical, which invested 1.04 billion RMB, highlighting potential areas for growth[143]. Market Position and Strategy - The company is positioned within a competitive landscape where major players include China National Pharmaceutical Group, China Resources Pharmaceutical, and Qilu Pharmaceutical, which are ranked as the top three in the industry[57]. - The company aims to become a health industry group centered on innovative traditional Chinese medicine, focusing on "innovative TCM R&D" and "management reform" to enhance core competitiveness[76]. - The company is focusing on market expansion and strategic acquisitions to enhance its product portfolio and market presence[119]. - The company is expected to benefit from the increasing demand for traditional Chinese medicine and the ongoing internationalization and cultural promotion efforts in the sector[51]. Compliance and Governance - The report includes a standard unqualified audit opinion from the accounting firm, ensuring the accuracy and completeness of the financial statements[5]. - The company has confirmed that all board members attended the board meeting, ensuring collective responsibility for the report's content[5]. - The company has implemented various training programs to enhance governance awareness among its directors and management[182]. - The company has established a remuneration and assessment committee to determine and distribute the remuneration for directors, supervisors, and senior management[194]. Risks and Challenges - The pharmaceutical industry faces systemic challenges, but government policies are fostering innovation and competitiveness, particularly in traditional Chinese medicine[49]. - The company faces risks related to policy changes in the pharmaceutical industry, including price controls and market competition, which may impact profitability[173]. - The company recognizes the risks associated with mergers and acquisitions, including the uncertainty in target selection and post-merger integration[175]. - The risk of declining product gross margins due to fluctuations in traditional Chinese medicine material prices may impact profitability[176]. Employee and Corporate Culture - The company has engaged in various cultural activities to enhance employee cohesion and promote a positive corporate culture[44]. - The company is focused on building a strategic talent system to drive innovation and support high-quality development, implementing various training programs for management and professional staff[47]. Industry Overview - The pharmaceutical manufacturing industry in China achieved a revenue of CNY 2.53 trillion in 2024, remaining stable compared to the previous year, with a total profit of CNY 342.07 billion, a decrease of 1.10% year-on-year[52]. - The sales revenue of the pharmaceutical market in the first half of 2024 reached CNY 947.7 billion, reflecting a slight decline of 1.90% year-on-year, with public hospitals accounting for 60.50% of the market share[54]. - The government is promoting the modernization of traditional Chinese medicine to enhance quality and international competitiveness[115].

Financial Performance - Revenue for Q1 2025 was CNY 418,083,503.37, a decrease of 4.62% compared to CNY 438,354,992.77 in the same period last year[6] - Net profit attributable to shareholders increased by 25.74% to CNY 88,257,931.44 from CNY 70,192,886.65 year-on-year[6] - The net profit after deducting non-recurring gains and losses rose by 31.41% to CNY 70,827,987.91[6] - Basic and diluted earnings per share increased by 25.00% to CNY 0.20[6] - Total operating revenue for Q1 2025 was CNY 418,083,503.37, a decrease of 4.3% compared to CNY 438,354,992.77 in Q1 2024[29] - Net profit for Q1 2025 reached CNY 88,724,501.72, an increase of 30.1% compared to CNY 68,264,902.22 in Q1 2024[30] - The total comprehensive income for Q1 2025 reached ¥88,724,501.72, compared to ¥68,264,902.22 in Q1 2024, indicating a year-over-year increase of about 30%[32] - The basic and diluted earnings per share for Q1 2025 were both ¥0.20, up from ¥0.16 in Q1 2024, reflecting a 25% increase[32] Cash Flow and Liquidity - Net cash flow from operating activities decreased by 53.25% to CNY 21,926,099.35 compared to CNY 46,898,258.14 in the previous year[6] - Cash flow from operating activities for Q1 2025 was ¥21,926,099.35, a decrease from ¥46,898,258.14 in Q1 2024, showing a decline of approximately 53%[35] - The company's cash and cash equivalents decreased to CNY 187,229,940.96 as of March 31, 2025, from CNY 308,459,619.06 at the end of 2024[24] - The total cash and cash equivalents at the end of Q1 2025 were ¥172,813,963.89, down from ¥249,825,449.24 at the end of Q1 2024, a decrease of approximately 30.8%[37] - The cash received from sales of goods and services in Q1 2025 was ¥378,348,512.33, down from ¥410,322,321.30 in Q1 2024, indicating a decline of about 7.8%[35] - The company reported a net cash outflow from operating activities of ¥372,472,153.73 in Q1 2025, compared to ¥381,238,666.06 in Q1 2024, showing a slight improvement in cash management[35] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,150,000,609.09, a decrease of 3.57% from CNY 3,266,573,464.59 at the end of the previous year[6] - The company's equity increased to CNY 1,759,485,558.99 as of March 31, 2025, from CNY 1,734,868,298.65 at the end of 2024[26] - Total liabilities decreased to CNY 1,390,515,050.10 as of March 31, 2025, compared to CNY 1,531,705,165.94 at the end of 2024[26] Investment and Acquisitions - The company acquired a 30% stake in Guangdong Jinan Gene Drug Engineering Research Center Co., Ltd. for RMB 41.43 million on January 27, 2025[15] - The company confirmed investment income from technology transfer agreements totaling RMB 2.13 million for "Fumai Ding Capsules" and "Qingnao Jiangya Granules" during the reporting period[15] - The company plans to increase its stake in the company by investing between RMB 2 million and RMB 4 million from February 11 to August 10, 2025[16] - The company signed a drug listing license transfer agreement for "Xiao Qinglong Capsules" on March 25, 2025[19] - The company transferred 100% equity of Zheya Bio for RMB 20 million on February 22, 2025[18] - The company is set to receive a total of RMB 154.68 million from the sale of a 51% stake in Changsha Kexin Tumor Hospital Co., Ltd.[21] - The company entered into technology transfer contracts worth RMB 19.1 million to shorten R&D cycles and reduce costs[20] - The company plans to establish a joint venture in Hong Kong with a registered capital of HKD 20 million, holding 35%[19] Cost Management - The decline in revenue was attributed to price reductions due to drug procurement policies and the exclusion of certain subsidiaries from consolidation[10] - The company has focused on cost control and efficiency improvements, which contributed to the increase in profitability[10] - Total operating costs for Q1 2025 were CNY 340,146,773.39, down 9.5% from CNY 376,020,762.61 in Q1 2024[30]

（经公司第六届董事会第二次会议审议） 湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 湖南方盛制药股份有限公司 防止大股东及关联方占用公司资金管理制度 第一章 总则 第一条 为了建立防止大股东或实际控制人占用湖南方盛制 药股份有限公司（以下简称"公司"）资金的长效机制，杜绝大 股东及关联方资金占用行为的发生，根据《中华人民共和国公司 法》（以下简称"《公司法》"）、《中华人民共和国证券法》 《上市公司监管指引第 8 号——上市公司资金往来、对外担保的 监管要求》等法律、法规及规范性文件，以及《湖南方盛制药股 份有限公司章程》（以下简称"公司章程"）的有关规定，制定 本制度。 第二条 公司董事和高级管理人员对维护公司资金安全有法 定义务。 第三条 本制度所称资金占用包括但不限于：经营性资金占 用和非经营性资金占用。经营性资金占用是指大股东及关联方通 过采购、销售等生产经营环节的关联交易产生的资金占用；非经 营性资金占用是指为大股东及关联方垫付工资与福利、保险、广 告等费用和其他支出、为大股东及关联方有偿或无偿直接或间接 拆借资金、代偿债务及其他在没有商品 ...

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 湖南方盛制药股份有限公司 对外担保管理办法 （经公司第六届董事会第二次会议审议） 第一章 总则 第一条 为了保护投资者的合法权益，规范湖南方盛制药股 份有限公司（下称"公司"）的对外担保行为，有效防范公司对 外担保风险，确保公司资产安全，根据《中华人民共和国公司法》 （以下简称"《公司法》"）、《上市公司监管指引第 8 号—— 上市公司资金往来、对外担保的监管要求》《上海证券交易所上 市公司自律监管指引第 1 号——规范运作》《上海证券交易所股 票上市规则》（以下简称"《上市规则》"）、等法律、法规、 规范性文件以及《湖南方盛制药股份有限公司公司章程》（以下 简称"《公司章程》"）的有关规定，结合公司的实际情况，特 制定本办法。 第二条 本办法所称对外担保系指公司以第三人的身份为债 务人对债权人所负的债务提供担保，当债务人不履行债务时，由 公司按照约定履行债务或者承担责任的行为。本制度所述对外担 保包括公司对全资子公司、控股子公司、参股子公司提供的担保。 第三条 公司对外担保实行统一管理，非经公司董事会或 ...